Lista de obras -

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

artículo científico publicado en 2004

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

artículo científico publicado en 2006

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

artículo científico publicado en 2005

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

artículo científico publicado en 2008

Analysis of treatment effectiveness in longitudinal observational data

artículo científico publicado en 2007

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

artículo científico publicado en 2012

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

artículo científico publicado en 2005

Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.

artículo científico publicado en 2012

Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs

artículo científico publicado en 2004

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

artículo científico publicado en 2015

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence ⬇️

artículo científico publicado el 7 de septiembre de 2010

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

artículo científico publicado en 2010

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics

artículo científico publicado en 2011

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia

artículo científico publicado en 2007

Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database

artículo científico publicado en 2013

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

artículo científico publicado en 2009

Clinical comparability of schizophrenia patients at two public mental health systems.

artículo científico publicado en 2003

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia

artículo científico publicado en 2007

Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes

artículo científico publicado en 2015

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

artículo científico publicado en 2012

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

artículo científico publicado en 2012

Corrigendum to "Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials" [Shizophr. Res. 130 (2011) 11–19]

scholarly article published in Schizophrenia Research

Cost of antipsychotic polypharmacy in the treatment of schizophrenia

artículo científico publicado en 2008

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

artículo científico publicado en 2009

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

artículo científico publicado en 2011

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

artículo científico publicado en 2006

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

scientific article published on 25 January 2011

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia ⬇️

artículo científico publicado el 26 de noviembre de 2010

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

artículo científico publicado en 2012

Costs associated with attempted suicide among individuals with bipolar disorder

artículo científico publicado el 1 de junio de 2010

Costs of treating patients with schizophrenia who have illness-related crisis events

artículo científico publicado en 2008

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

artículo científico publicado en 2011

Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation

artículo científico publicado en 2011

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

artículo científico publicado en 2014

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

artículo científico publicado en 2015

Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus

artículo científico publicado en 2014

Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials

artículo científico publicado en 2010

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

artículo científico publicado en 2014

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

artículo científico publicado en 2011

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia

artículo científico publicado en 2010

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.

artículo científico publicado en 2010

Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease

artículo científico publicado en 2016

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

artículo científico publicado en 2012

Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia

scientific article published on 14 December 2012

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

artículo científico publicado en 2015

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

artículo científico publicado en 2015

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study

artículo científico publicado en 2011

Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome ⬇️

artículo científico publicado el 1 de octubre de 2010

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia ⬇️

artículo científico publicado el 9 de febrero de 2011

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan

artículo científico publicado en 2012

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

artículo científico publicado en 2010

Item response analysis of the Positive and Negative Syndrome Scale

artículo científico publicado en 2007

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

artículo científico publicado en 2014

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study

artículo científico publicado en 2012

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder

artículo científico publicado en 2007

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

artículo científico publicado en 2009

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

artículo científico publicado en 2006

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

artículo científico publicado en 2009

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

artículo científico

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder

artículo científico publicado en 2007

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

artículo científico publicado en 2009

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

artículo científico publicado en 2013

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

artículo científico publicado en 2012

Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods

artículo científico publicado en 2009

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

artículo científico

Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics

artículo científico publicado en 2009

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.

scientific article published on 20 December 2007

Predicting psychiatric hospital admission among adults with schizophrenia

artículo científico publicado en 2011

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

artículo científico publicado en 2008

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs

artículo científico publicado en 2016

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

artículo científico publicado en 2012

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan

artículo científico publicado en 2011

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

artículo científico publicado en 2009

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

artículo científico publicado en 2013

Predictors of switching antipsychotic medications in the treatment of schizophrenia

artículo científico publicado en 2010

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

artículo científico publicado en 2006

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

artículo científico publicado en 2011

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives ⬇️

artículo científico publicado el 1 de octubre de 2010

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms

artículo científico publicado en 2011

Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools

artículo científico publicado en 2007

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

artículo científico publicado en 2012

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study

artículo científico publicado en 2011

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

artículo científico publicado en 2008

Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.

artículo científico publicado en 2008

The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry

artículo científico publicado en 2007

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

artículo científico publicado en 2006

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

artículo científico publicado en 2010

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial

artículo científico publicado en 2013

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy

artículo científico publicado en 2013

The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.

artículo científico publicado en 2004

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

artículo científico publicado en 2011

The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials

artículo científico publicado en 2008

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

artículo científico publicado en 2012

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

artículo científico publicado en 2006

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.

artículo científico publicado en 2008

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

artículo científico publicado en 2011

Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence

artículo científico publicado en 2011

Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone

artículo científico publicado en 2007

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients

artículo científico publicado en 2009

Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.

artículo científico publicado en 2012

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

artículo científico publicado en 2012

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia

artículo científico publicado en 2011

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

artículo científico publicado en 2012

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

artículo científico publicado en 2012

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

artículo científico publicado en 2005

Lista de obras de

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Analysis of treatment effectiveness in longitudinal observational data

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.

Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence ⬇️

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia

Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Clinical comparability of schizophrenia patients at two public mental health systems.

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia

Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

Corrigendum to "Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials" [Shizophr. Res. 130 (2011) 11–19]

Cost of antipsychotic polypharmacy in the treatment of schizophrenia

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia ⬇️

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Costs associated with attempted suicide among individuals with bipolar disorder

Costs of treating patients with schizophrenia who have illness-related crisis events

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus

Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.

Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study

Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome ⬇️

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia ⬇️

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Item response analysis of the Positive and Negative Syndrome Scale

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.

Predicting psychiatric hospital admission among adults with schizophrenia

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives ⬇️